Refine Search

...should consider getting MRI besides mammography," said Dr. Stephen Feig, a radiology professor at MountSinaiSchoolofMedicineinNewYork and past president of the Society of Breast Imaging. He had no role in the new research, which was...

...extraordinary advantage," said Dr. Adam I. Levine, director of the anesthesiology residency program at MountSinaiSchoolofMedicineinNewYork. "If you have to think through the problem yourself and get your answer, you learn it better." Students...

...much of the country. But how many will use sunscreen? Dr. James Spencer, a dermatologist from the MountSinaiSchoolofMedicineinNewYork and a spokesman for the American Academy of Dermatology, says not nearly enough. A Boston University...

...lethal drugs at the request of patients who have less than six months to live. Dr. Diane E. Meier of MountSinaiSchoolofMedicineinNewYork City sent questionaires to 3,102 doctors, and 1,902 answered anonymously. The results were published...

...lethal drugs at the request of patients who have less than six months to live. Dr. Diane E. Meier of MountSinaiSchoolofMedicineinNewYork City sent questionaires to 3,102 doctors, and 1,902 answered anonymously. The results were published...

Prostate cancer sufferers who have a family history of the disease are more likely to have a relapse and more likely to die from the disease than are men without a family history, according to Dr. Patrick Kupelian of the Cleveland Clinic Foundation in Ohio. Men with such a history -- either a father or a brother with prostate cancer -- should undergo screening at an earlier age and, when a tumor is detected, should be treated more aggressively, he told an American Cancer Society briefing for reporters in Newport Beach, Calif., last week.

...the prostate, and maybe spare some men from having unnecessary surgery, said Dr. Anna Ferrari of the MountSinaiSchoolofMedicineinNewYork. Prostate cancer is the second leading cancer killer in American men, with an expected death toll this...

Taken separately, the studies on the drug - Eli Lilly & Co.'s solanezumab - missed their main goals of significantly slowing the mind-robbing disease or improving activities of daily living. But pooled results found 34 percent less mental decline in mild Alzheimer's patients compared to those on a fake treatment for 18 months.

...extraordinary advantage," said Dr. Adam I. Levine, director of the anesthesiology residency program at MountSinaiSchoolofMedicineinNewYork. "If you have to think through the problem yourself and get your answer, you learn it better." Students...